Biorab Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to global rabies control initiatives, proven efficacy of rabies biologics, government vaccination programs, increased animal bite awareness, hospital emergency protocols.

The growth in the forecast period can be attributed to expansion of rabies elimination goals, rising public health funding, improved rural healthcare access, growth in emergency care infrastructure, increased surveillance of zoonotic diseases. Major trends in the forecast period include growing focus on rabies prevention programs, rising demand for post exposure prophylaxis, expansion of public health vaccination initiatives, improved access to anti rabies biologics, strengthening emergency infectious disease response.

The rising incidence of rabies is expected to drive the growth of the biorab market going forward. Rabies is a viral disease that affects the central nervous system (CNS) and is caused by the rabies virus, a member of the Rhabdoviridae family. The increasing incidence of rabies is largely due to the growing population of unvaccinated stray dogs, which serve as primary transmitters, as well as limited access to post-exposure prophylaxis (PEP) in rural areas, delaying timely treatment. Biorab helps reduce rabies transmission and fatalities by providing effective post-exposure prophylaxis and supporting vaccination programs, particularly in regions with limited healthcare access. For example, in April 2024, the South Dakota Department of Health, a US-based government agency, reported that rabies cases in South Dakota increased by 122% in 2023, with 20 animals testing positive compared to 9 in 2022. Consequently, the rising incidence of rabies is contributing to the growth of the biorab market.

The growth of the biorab market is also supported by increasing research and development activities. R&D involves the systematic exploration and creation of new knowledge, products, or technologies through research and experimentation. Rising R&D efforts are driven by the demand for innovative solutions to address emerging health threats and enhance treatment efficacy. For Biorab, R&D supports innovations in rabies prevention and treatment, improving vaccine efficacy and safety profiles, enabling wider adoption, and promoting better public health outcomes. For instance, in July 2025, Eurostat, a Luxembourg-based statistical agency, reported that total government budget allocations for research and development across the EU reached approximately €127.91 billion in 2024, marking a 3.4% increase from €123.67 billion in 2023. Therefore, increasing research and development activities are contributing to the growth of the biorab market.

The expanding geriatric population is expected to further boost the growth of the biorab market. The geriatric population includes individuals aged 65 years and older, who often experience age-related health conditions and require specialized healthcare services. The increase in this population segment is due to rising life expectancy, advancements in healthcare, improved living standards, and declining birth rates. Biorab supports geriatric patients by offering specialized healthcare solutions that address age-related challenges, enhance disease management, and improve overall quality of life through tailored diagnostics and therapies. For example, in May 2024, the US Administration for Community Living reported that 17.3% of the population was aged 65 or older in 2022, a figure projected to rise to 22% by 2040. Consequently, the growing geriatric population is driving the expansion of the biorab market.

Major companies operating in the biorab market are Vowcare Products Pvt. Ltd., Bioethics Lifesciences Pvt. Ltd.

North America was the largest region in the biorab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biorab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biorab market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately influenced the biorab market by increasing costs related to biologic production materials and vaccine distribution logistics. These impacts are most evident in public health programs and hospital procurement channels. Higher tariffs have added pressure on large scale vaccination budgets. At the same time, tariffs are encouraging domestic biologics manufacturing capacity. This supports long term availability of rabies prevention therapies.

The biorab market research report is one of a series of new reports that provides biorab market statistics, including biorab industry global market size, regional shares, competitors with a biorab market share, detailed biorab market segments, market trends and opportunities, and any further data you may need to thrive in the biorab industry. This biorab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biorab is a medication used to manage acid-related conditions, including acid reflux, peptic ulcer disease, and Zollinger-Ellison syndrome, by reducing stomach acid production. It helps relieve symptoms, supports ulcer healing, and prevents complications from excessive acid secretion.

The main indications for Biorab include pre-exposure prophylaxis and post-exposure prophylaxis of rabies. Pre-exposure prophylaxis (PrEP) is a preventive approach in which individuals at high risk take medication to lower the chance of infection. Biorab is distributed through hospitals, clinics, retail pharmacies, online pharmacies, and public health programs, and is used by geriatric and pediatric populations, as well as in veterinary applications.

The biorab market consists of sales of products including omeprazole, lansoprazole, and esomeprazole. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.